Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans.
The activity of caspofungin (CFG) combined with amphotericin B (AMB) against azole-resistant Candida albicans was evaluated in vitro (chequerboard) and in vivo (murine). CFG+AMB resulted in positive interactive effects in vitro (fractional inhibitory concentration index 0.75). Compared with untreated controls, CFG+AMB prolonged mouse survival (P = 0.006) and compared with AMB alone, CFG+AMB prolonged mouse survival (P = 0.36); however, the latter difference was not significant. CFG+AMB treatment significantly reduced kidney cfu compared with untreated controls and CFG-treated groups (P < or = 0.05 for both comparisons). In addition, this combination reduced brain cfu significantly compared with untreated controls and AMB-treated mice (P = 0.005 and 0.05, respectively).
Hossain
Mohammad A
MA
Center for Medical Mycology, Department of Dermatology, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106-5028, USA.
Reyes
Guadalupe H
GH
Long
Lisa A
LA
Mukherjee
Pranab K
PK
Ghannoum
Mahmoud A
MA
D000666:Amphotericin B / Q000008:administration & dosage*; D000818:Animals; D001393:Azoles / Q000008:administration & dosage / Q000494:pharmacology*; D002176:Candida albicans / Q000187:drug effects* / Q000254:growth & development; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology; D000077336:Caspofungin; D025141:Drug Resistance, Fungal / Q000187:drug effects / Q000502:physiology; D004359:Drug Therapy, Combination; D054714:Echinocandins; D006801:Humans; D055666:Lipopeptides; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010455:Peptides / Q000008:administration & dosage*; D010456:Peptides, Cyclic
D001393:Azoles; D054714:Echinocandins; D055666:Lipopeptides; D010455:Peptides; D010456:Peptides, Cyclic; D000666:Amphotericin B; D000077336:Caspofungin